Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CLSD Stock Forecast 2025-2026
$0.81
Current Price
$63.12M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CLSD Price Targets
+885.2%
To High Target of $8.00
+515.8%
To Median Target of $5.00
+269.5%
To Low Target of $3.00
CLSD Price Momentum
+1.3%
1 Week Change
+2.5%
1 Month Change
-36.7%
1 Year Change
-14.7%
Year-to-Date Change
-50.8%
From 52W High of $1.65
+16.0%
From 52W Low of $0.70
📊 TOP ANALYST CALLS
Did CLSD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Clearside is one of their latest high-conviction picks.
Latest CLSD Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, CLSD has a bullish consensus with a median price target of $5.00 (ranging from $3.00 to $8.00). Currently trading at $0.81, the median forecast implies a 515.8% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Annabel Samimy at Stifel, projecting a 885.2% upside. Conversely, the most conservative target is provided by Serge Belanger at Needham, suggesting a 269.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLSD Analyst Ratings
7
Buy
0
Hold
0
Sell
CLSD Price Target Range
Low
$3.00
Average
$5.00
High
$8.00
Current: $0.81
Latest CLSD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLSD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 23, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $5.00 |
| May 16, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $5.00 |
| May 15, 2025 | Needham | Serge Belanger | Buy | Maintains | $3.00 |
| Apr 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $4.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $6.00 |
| Mar 28, 2025 | Needham | Serge Belanger | Buy | Maintains | $4.00 |
| Mar 28, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $5.00 |
| Mar 28, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $6.00 |
| Mar 6, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $6.00 |
| Mar 6, 2025 | Needham | Serge Belanger | Buy | Reiterates | $6.00 |
| Nov 15, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $6.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $6.00 |
| Nov 13, 2024 | Needham | Serge Belanger | Buy | Reiterates | $6.00 |
| Oct 14, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $6.00 |
| Oct 10, 2024 | Needham | Serge Belanger | Buy | Maintains | $6.00 |
| Aug 27, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $5.00 |
| Aug 21, 2024 | Chardan Capital | Daniil Gataulin | Buy | Initiates | $6.00 |
| Aug 13, 2024 | Needham | Serge Belanger | Buy | Reiterates | $4.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $5.00 |
| Jul 30, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $5.00 |
Clearside Biomedical Inc. (CLSD) Competitors
The following stocks are similar to Clearside based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Clearside Biomedical Inc. (CLSD) Financial Data
Clearside Biomedical Inc. has a market capitalization of $63.12M with a P/E ratio of -1.7x. The company generates $3.76M in trailing twelve-month revenue with a 91.0% profit margin.
Revenue growth is +913.0% quarter-over-quarter, while maintaining an operating margin of -223.4% and return on equity of +88.4%.
Valuation Metrics
Market Cap
$63.12M
Enterprise Value
$102.60M
P/E Ratio
-1.7x
PEG Ratio
-1.6x
Price/Sales
16.8x
Growth & Margins
Revenue Growth (YoY)
+913.0%
Gross Margin
+89.4%
Operating Margin
-223.4%
Net Margin
+91.0%
EPS Growth
+913.0%
Financial Health
Cash/Price Ratio
+21.6%
Current Ratio
3.2x
Debt/Equity
-1.2x
ROE
+88.4%
ROA
-54.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Clearside Biomedical Inc. (CLSD) Business Model
About Clearside Biomedical Inc.
What They Do
Develops therapies for eye diseases.
Business Model
The company utilizes its proprietary SCS Microinjector technology to deliver drugs directly to the back of the eye, focusing on conditions such as macular edema and retinal vein occlusion. By improving drug delivery, Clearside Biomedical aims to enhance treatment efficacy and minimize side effects, creating a competitive edge in the ophthalmic pharmaceutical market.
Additional Information
Clearside Biomedical's pipeline addresses severe visual impairments and blindness, positioning the company as a crucial player in the growing demand for innovative ocular therapies. Its advancements in drug delivery methods are significant for the treatment of eye diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
32
CEO
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Country
United States
IPO Year
2016
Website
clearsidebio.comClearside Biomedical Inc. (CLSD) Latest News & Analysis
Latest News
Quick Summary
Clearside Biomedical (Nasdaq: CLSD) will showcase its suprachoroidal injection platform for retinal treatments at the CTS Meeting on June 21, 2025, highlighting its CLS-AX therapy.
Why It Matters
Clearside Biomedical's advancements in retinal therapies via the SCS delivery platform could enhance treatment options, potentially boosting the company's market position and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Clearside Biomedical (CLSD) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects.
Why It Matters
Clearside Biomedical's upgrade to a Zacks Rank #2 signals increased investor confidence, potentially driving stock demand and price appreciation. Enhanced earnings prospects may attract more buyers.
Source: Zacks Investment Research
Market Sentiment:
Positive
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
1 month ago
Quick Summary
Clearside Biomedical (Nasdaq: CLSD) will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on May 27, 2025, at 9:00 a.m. ET.
Why It Matters
Management's participation in a prominent forum may signal upcoming developments or insights into Clearside Biomedical's pipeline, potentially influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
1 month ago
Quick Summary
Clearside Biomedical announced a successful FDA meeting for its CLS-AX Phase 3 program in Wet AMD, highlighting flexible dosing and multiple achieved milestones. Financial results for Q1 2025 were also shared.
Why It Matters
The FDA's endorsement of CLS-AX for Phase 3 trials enhances Clearside Biomedical's growth potential and market position in treating Wet AMD, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Clearside Biomedical (CLSD) reported a quarterly loss of $0.11 per share, beating the Zacks estimate of $0.12 and improving from a loss of $0.17 per share a year earlier.
Why It Matters
Clearside Biomedical's smaller-than-expected loss indicates improving financial performance, which may boost investor confidence and positively influence stock prices.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Strong clinical evidence endorses the Suprachoroidal Platform for treating various macular diseases, potentially broadening its standard of care in ophthalmology.
Why It Matters
Strong clinical evidence for the Suprachoroidal Platform suggests potential growth in market share and revenue for companies involved, impacting stock performance and investor sentiment in the healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CLSD Stock
What is Clearside Biomedical Inc.'s (CLSD) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Clearside Biomedical Inc. (CLSD) has a median price target of $5.00. The highest price target is $8.00 and the lowest is $3.00.
Is CLSD stock a good investment in 2026?
According to current analyst ratings, CLSD has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLSD stock?
Wall Street analysts predict CLSD stock could reach $5.00 in the next 12 months. This represents a 515.8% increase from the current price of $0.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Clearside Biomedical Inc.'s business model?
The company utilizes its proprietary SCS Microinjector technology to deliver drugs directly to the back of the eye, focusing on conditions such as macular edema and retinal vein occlusion. By improving drug delivery, Clearside Biomedical aims to enhance treatment efficacy and minimize side effects, creating a competitive edge in the ophthalmic pharmaceutical market.
What is the highest forecasted price for CLSD Clearside Biomedical Inc.?
The highest price target for CLSD is $8.00 from Annabel Samimy at Stifel, which represents a 885.2% increase from the current price of $0.81.
What is the lowest forecasted price for CLSD Clearside Biomedical Inc.?
The lowest price target for CLSD is $3.00 from Serge Belanger at Needham, which represents a 269.5% increase from the current price of $0.81.
What is the overall CLSD consensus from analysts for Clearside Biomedical Inc.?
The overall analyst consensus for CLSD is bullish. Out of 10 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are CLSD stock price projections?
Stock price projections, including those for Clearside Biomedical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 6, 2025 8:45 PM UTC